Clinical Trials on Allogenic Bone Marrow Transplantation in Australia

Total 266 results

Medical University of Vienna

Unknown

Vitamin D3 Substitution in Vitamin D Deficient Kidney Transplant Recipients (VITA-D)

Vitamin D Deficiency | Kidney Transplantation | Renal Osteodystrophy

Austria
AbbVie

Completed

A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review (METER)

Myelofibrosis

Argentina, Australia, Brazil, Canada, Colombia, Greece, Italy, Mexico, Poland, Portugal, Romania, Taiwan, Turkey, United States
Incyte Corporation

Completed

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Polycythemia Vera | Myelofibrosis | Thrombocythemia

Spain, United States, Germany, Austria, Belgium, Italy, Poland
Central European Leukemia Study Group

Unknown

Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

Chronic Myeloid Leukemia

Austria
Celgene

Recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

Primary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis

France, Belgium, Spain, Australia, Canada, United States, Korea, Republic of, Romania, Japan, Israel, Italy, Austria, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Argentina, Chile, Colombia and more
Ellipses Pharma

Recruiting

Study to Evaluate the Safety and Tolerability of EP0042

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Australia, Netherlands, United Kingdom
Medical University of Graz

Completed

Screening for Pulmonary Vascular Changes in Patients With Chronic Myeloproliferative Diseases

Myeloproliferative Disorders | Pulmonary Hypertension

Austria
GCP-Service International West GmbH
Saint-Louis Hospital, Paris, France; Groupe Francophone des Myelodysplasies; Australasian... and other collaborators

Active, not recruiting

Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (IMpress)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Germany, France, Australia
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Novartis Pharmaceuticals

Completed

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Bone Marrow Diseases | Hematologic Diseases | Blood Coagulation Disorders | Hemorrhagic Disorders | Primary Myelofibrosis | Myeloproliferative Disorders | Polycythemia Vera | Thrombocytosis | Essential Thrombocythemia | Blood Platelet Disorders

United Kingdom, Belgium, Canada, France, Australia, Netherlands, Spain, Denmark, Ireland, Italy, Germany
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

Myelofibrosis

Italy, Spain, United States, Australia, France, Germany, Greece, Hungary, Israel, Korea, Republic of, Poland, Romania
Sanofi

Completed

Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia

Hematopoietic Neoplasm

United States, Spain, France, Canada, Australia, Korea, Republic of, Germany, Italy, United Kingdom
Poitiers University Hospital
University Medical Center Groningen; Imperial College London; University of Liege and other collaborators

Recruiting

International Chronic Myeloid Leukemia Pediatric Study (ICMLPed)

Chronic Myeloid Leukemia

Denmark, China, Germany, Australia, Belgium, Brazil, Chile, Croatia, Czechia, France, Greece, Japan, Lebanon, Poland, Spain, Turkey, Austria, Belarus, Netherlands, Slovakia
AbbVie

Active, not recruiting

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

Myelofibrosis (MF)

United States, Argentina, Australia, Brazil, Bulgaria, Chile, Hungary, Israel, Italy, Japan, Korea, Republic of, Spain, Sweden, Turkey
Keros Therapeutics, Inc.

Recruiting

A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).

Iron Deficiency Anemia

Australia, Israel, Romania
Incyte Corporation
Novartis

Completed

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Myelofibrosis

France, United Kingdom, China, United States, Netherlands, Germany, Italy, Austria
Kartos Therapeutics, Inc.

Recruiting

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Myelofibrosis

United States, France, Australia, Spain, Germany, Bulgaria, Israel, Italy, Poland
St. Anna Kinderkrebsforschung

Completed

Allogeneic Stem Cell Transplantation for Children With CML

Chronic Myeloid Leukemia

Austria, Czechia, Italy
Sumitomo Pharma America, Inc.

Recruiting

A Study of Oral TP-3654 in Patients With Myelofibrosis

Myelofibrosis

United States, Belgium, France, Japan, Australia, Italy, United Kingdom
Medical University Innsbruck
University Hospital, Bonn; Universitätsklinikum Leipzig

Recruiting

Sterile Inflammation and Molecular Aberrations in MDS (InflamGen)

Myelodysplastic Syndromes

Austria
Sierra Oncology LLC - a GSK company

Completed

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, France, Canada, Germany, Australia
Humanigen, Inc.

Suspended

Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)

Myelodysplastic Syndrome (MDS) | Myelofibrosis (MF)

United States, Australia
Medical University of Graz

Completed

Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

Austria
Bristol-Myers Squibb

Completed

A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

Australia, Italy, Canada, United States, Germany, Spain, France
Pfizer
Eli Lilly and Company

Completed

Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy

Cancer Pain | Bone Metastasis

China, Spain, Korea, Republic of, Australia, Israel, Japan, Poland, Slovakia, Romania, Austria, Hungary, United Kingdom, Argentina, Brazil, Chile, Czechia
University Hospital Freiburg

Completed

Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment

Myelodysplastic Syndromes | Fanconi Anemia | Dyskeratosis Congenita | Pearson Marrow-pancreas Syndrome | Shwachman-diamond Syndrome

Spain, Germany, Switzerland, Austria, Netherlands, Italy, Czech Republic, Belgium, Denmark, Ireland
Peter MacCallum Cancer Centre, Australia
GlaxoSmithKline; Celgene Corporation

Completed

A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia (Aza-E)

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)

Australia
Celgene

Completed

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q (MDS-005)

Anemia

United States, Belgium, Spain, United Kingdom, Austria, Canada, Germany, Portugal, France, Australia, Israel, Japan, Italy, Czechia, Poland, Turkey
Sierra Oncology, Inc.

Completed

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis (Simplify 1)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, France, Germany, Spain, Israel, Bulgaria, Romania, Japan, Taiwan, Korea, Republic of, Australia, Belgium, Canada, Netherlands, Singapore, Poland, Hungary, Denmark, Sweden, United Kingdom, Czechia, Austria
Alexion Pharmaceuticals

Completed

Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PNH

Korea, Republic of, Australia
Sierra Oncology LLC - a GSK company

Completed

A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Canada, Hungary, Israel, Spain, United States, Australia, Taiwan, Singapore, Germany, Italy, France, Belgium, New Zealand, Austria, United Kingdom, Denmark, Bulgaria, Poland, Czechia, Romania, Sweden
Keros Therapeutics, Inc.

Recruiting

A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Cytopenia

Australia, Spain, United States, Israel, France, Germany, New Zealand, Czechia
Imago BioSciences, Inc., a subsidiary of Merck...

Active, not recruiting

Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

Primary Myelofibrosis | Thrombocythemia, Essential

United States, Australia, Hong Kong, Germany, Italy, New Zealand, United Kingdom
Imago BioSciences, Inc., a subsidiary of Merck...

Completed

Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

Essential Thrombocythemia

United States, Australia, New Zealand, United Kingdom, Hong Kong, Germany, Italy
Novartis Pharmaceuticals

Terminated

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Myelodysplastic Syndromes

United States, Spain, Italy, Singapore, Korea, Republic of, Israel, Australia
AbbVie
Celgene; Genentech, Inc.

Completed

A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS)

United States, Australia, Germany
Novartis Pharmaceuticals

Completed

Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

CHRONIC MYELOGENOUS LEUKEMIA

Canada, Australia, Spain, Argentina, France, Brazil
Clinical Hub for Interventional Research (CHOIR)
The University of New South Wales; Australian National University

Recruiting

Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS (CELESTIAL-MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Australia
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukaemia (AML)

France, Australia
Race Oncology Ltd
Astex Pharmaceuticals, Inc.

Withdrawn

A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS (BISECT)

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Higher Risk Myelodysplastic Syndrome

Australia
ADARx Pharmaceuticals, Inc.
ADARx Australia Pty Ltd

Recruiting

Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Australia
Cleave Therapeutics, Inc.

Completed

Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Acute Myeloid Leukemia, in Relapse

United States, Australia
Novartis Pharmaceuticals

Terminated

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. (ReTHINK)

Myelofibrosis With High Molecular Risk Mutations

Belgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
GWT-TUD GmbH
Celgene

Recruiting

Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome. (LUSPLUS)

Myelodysplastic Syndromes

Austria, Germany, Spain, Switzerland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE)

Primary Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis | Post-Polycythemia Vera-Myelofibrosis

Belgium, Italy, Spain, Bulgaria, Turkey, Greece, Russian Federation, Austria, Canada, Japan, Germany
Kirby Institute
Celgene

Completed

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

Australia
Arbeitsgemeinschaft medikamentoese Tumortherapie
AOP Orphan Pharmaceuticals AG

Completed

Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response

Chronic Phase Chronic Myeloid Leukemia

Austria
Celgene

Completed

Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs)

Myelodysplastic Syndromes | Beta-thalassemia

Austria
Celgene

Completed

An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

Italy, United Kingdom, Germany, Australia, Bulgaria, France, Greece, Hungary, Netherlands, Poland, Spain
AbbVie

Active, not recruiting

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis (TRANSFORM-1)

Myelofibrosis (MF)

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Spain, Sweden, Taiwan, Turkey and more

Clinical Trials on Allogenic Bone Marrow Transplantation in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations